The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.
Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million suffer from symptomatic infection. WHO estimates that the global burden of dengue has risen 30-fold over the past 50 years, with over half of the world’s population at risk of the disease.
There is no licensed vaccine available to treat or prevent dengue fever, and efforts to develop one have been complicated by the fact that dengue is caused by four distinct dengue viruses, and a vaccine must target all four serotypes (DENV 1–4).
This phase 3 trial took place in dengue-endemic areas across five countries in Asia, a region that accounts for over 70% of the global dengue burden. The study involved 10 275 healthy children aged 2 to 14 years who were randomly assigned to receive three injections of the CYD-TDV vaccine (6851) or a placebo (3424) at 0, 6, and 12 months, and followed for up to 2 years.
The researchers recorded 250 dengue cases more than 28 days after the third injection—117 in the vaccine group and 133 in the placebo group, demonstrating an overall protective efficacy of 56.5%.
The vaccine also showed 88.5% efficacy after 3 doses against severe disease (dengue haemorrhagic fever) which leads to hospitalisation for over half a million people (mostly children) every year, and 67% against dengue-associated hospitalisation.
The Latest on: Dengue vaccine
[google_news title=”” keyword=”Dengue vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Dengue vaccine
- Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.on February 27, 2024 at 12:26 am
Limited, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat ...
- Japanese drug firm Takeda ties up with Hyderabad-based firm Biological E to manufacture dengue vaccineon February 27, 2024 at 12:20 am
Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine. The partnership marks a crucial step in the fight against the ...
- Japan's drug firm Takeda, Biological E tie up to manufacture dengue vaccineon February 27, 2024 at 12:11 am
Japanese drug firm Takeda on Tuesday said it has tied up with Hyderabad-based firm Biological E Ltd to manufacture its dengue vaccine.
- Takeda and India's Biological E. to accelerate access to dengue vaccine in endemic areason February 27, 2024 at 12:07 am
Takeda (NYSE:TAK) and India-based vaccines and pharmaceutical company Biological E, announced a strategic partnership to accelerate access to multi-dose vials of QDENGA, a vaccine that helps protect ...
- Japan's Takeda partners with India's Biological E. to boost dengue vaccine productionon February 26, 2024 at 10:07 pm
Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday. These doses will be ...
- Takeda, Biological E tie up for dengue vaccine productionon February 26, 2024 at 9:40 pm
Takeda and Biological E partner to increase global access to QDENGA vaccine, combating dengue fever in endemic countries.
- Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areason February 26, 2024 at 8:31 pm
Limited, which has deep expertise in vaccine manufacturing and longstanding support of public health programs around the world. Together, we will help combat dengue on a global scale by significantly ...
- Takeda Signs Manufacturing Partnership With India's Biological E. For Dengue Vaccine QDENGAon February 26, 2024 at 4:30 pm
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced late Monday a strategic manufacturing partnership with Indian vaccines and pharmaceutical firm Biological E. Ltd. to accelerate ...
- 'Time to try vaccines for dengue'on February 26, 2024 at 8:04 am
FORMER head of the Vaccine Expert Panel of the Department of Science and Technology (DoST) Dr. Nina Gloriani encouraged the public to take advantage of new discoveries such as the next-generation ...
- Brazil rolls out dengue vaccines as cases rise sharplyon February 24, 2024 at 9:00 pm
The health ministry warned earlier this year that the number of dengue cases could reach a record 5mn in 2024, a more than threefold increase from the 1.65mn cases recorded last year, which resulted ...
via Bing News